

June 2024

---

# Gavi Application Process Guidelines



## Key Audience

Immunisation programme managers and teams applying for Gavi support; Interagency Coordinating Committee (ICC) members; National Immunisation Technical Advisory Group (NITAG) members; partners supporting an application process.

## About these guidelines

This document outlines the types of support that Gavi offers as a part of its 2021-2025 strategic period, defines who is eligible to apply for support, and describes the end-to-end application process.

## Table of contents

<b>1</b>	<b>Introduction</b>	<b>3</b>
<b>2</b>	<b>Types of Gavi Support Available</b>	<b>4</b>
	Vaccine Support	5
	Vaccine Introduction Grants (VIGs) and Campaign Operational Support (Ops)	5
	Health System Strengthening (HSS) Support	5
	Equity Accelerator Funding	7
	EAF pre-requisites	7
	Difference between EAF and HSS	7
	Cold Chain Equipment Optimisation Platform (CCEOP)	7
	Partners' Engagement Framework (PEF) - Targeted Country Assistance (TCA)	8
	Other Support	9
	Yellow Fever Diagnostic Support	9
	Global Vaccine Stockpiles	9
	Support to Middle Income Countries (MICs)	9
	The COVAX Facility	9
	COVID-19 vaccine Delivery Support (CDS)	9
	Innovation Top-up	9
<b>3</b>	<b>The Application Process</b>	<b>10</b>
	New Approaches under Gavi 5.0 for Applying for Gavi Support	11
	Pathway 1 – Countries Conducting their FPP Process	12
	Pathway 2 – Countries Mid-Grant Cycle	16
	Review by the Independent Review Committee	17
	Application Approval	19
<b>4</b>	<b>Key strategic considerations for 'Gavi 5.0'</b>	<b>20</b>
	Gavi 5.0 Strategic Goals	20
	Gavi 5.0 Operating Principles	21
	Equity & Reaching Zero-Dose Children	22
	Using Zero-Dose Strategy to Strengthen Primary Health Care Across the Life Course	23
<b>5</b>	<b>Eligibility and Co-Financing</b>	<b>24</b>
	Gavi Eligibility Requirements	24
	Country Eligibility and Transition Status	26
	Co-Financing Requirements	28



## 1

## Introduction

Gavi's mission is to save children's lives and protect people's health by increasing equitable use of vaccines in lower-income countries. At the heart of the Gavi mission is our focus on equity, seeking to fully immunise every child with an intensified focus on reaching the most underserved populations and specifically zero-dose children.

Gavi's mission also recognises the fact that vaccines protect people at all stages of life by preventing both the primary causes of mortality in children (including diarrhoea and pneumonia) and preventing cancers later in life triggered by vaccine-preventable viral infections (such as cervical cancer from HPV and liver cancer from hepatitis B).

The Alliance's 2021-25 strategy – also known as “**Gavi 5.0**” – will build on the successes that have already been achieved

through the tremendous efforts of Gavi countries and our Alliance partners and further accelerate achievements towards universal immunisation.

**This document outlines the types of Gavi support available, eligibility requirements, and explains how to apply.**

These guidelines are complemented by [templates and detailed instructions](#) for requesting Gavi support. Gavi also provides [Programme Funding Guidelines](#) which help instruct how Gavi support can be used to overcome specific barriers to immunisation, such as those related to gender or demand, and for creating robust and sustainable immunisation systems, building on the technical guidance provided by partner organisations.

### Key Definitions

**Coverage:** Immunisation coverage is a key measure of immunisation system performance and is reported as the percentage of the population that have received one or more vaccines in relation to the overall population.

**Equity:** Equity is the organizing principle of the Alliance's 2021-2025 strategy, whose vision is to “leave no one behind with immunisation.” This entails a laser focus on using all Gavi levers to reach missed communities and zero-dose children with routine immunisation and to ensure that all children have an opportunity to survive, develop, and reach their full potential without discrimination, bias, or favouritism.

**Full portfolio planning (FPP):** The planning process that a country undertakes to map out their long term immunisation goals, objectives, activities, and the portfolio of Gavi support needed.

**The Gavi Theory of Change** is a collective process where country immunisation stakeholders gather together to map out how Gavi support is expected to contribute to a country's long term (3-5 years) immunisation goals and objectives. It is the shared thinking, alignment, and strategies for how to reach immunisation goals and how to best utilise a portfolio of Gavi support.

**Missed communities** are home to clusters of zero-dose and under-immunised children. These communities often face multiple deprivations and vulnerabilities, including socio-economic disparities and lack of access to health services, which can be further exacerbated by gender-related barriers.

**Under-immunised:** Under-immunised children are those who have not received a full course of routine vaccines. For operational purposes, Gavi defines under-immunised children as those who have not received a third dose of diphtheria-tetanus-pertussis containing vaccine (DTP3).

**Partners Engagement Framework (PEF):** Gavi provides funding to partners through the partners' engagement framework (PEF). This allows Gavi's partners to directly support countries' immunisation programmes.

**Senior Country Manager (SCM):** Your individual country focal point within the Gavi Secretariat.

**Zero-Dose Children** are those who have not received any routine vaccine. For operational purposes, Gavi defines zero-dose children as those who have not received a first dose of diphtheria-tetanus-pertussis containing vaccine (DTP1).

## 2 Types of Gavi Support Available

Gavi's support aims to assist countries in advancing their national immunisation plans and improving immunisation coverage and equity in a sustainable way. Our support includes:

### Vaccine Support



Routine



Campaign



Outbreak response



CHOLERA



EBOLA



HEPB



HPV



IPV  
INACTIVATED  
POLIO



JAPANESE  
ENCEPHALITIS



MEASLES



MALARIA



COVID-19



MEASLES  
RUBELLA




MENING.



PENTA  
DTP-HEPB-HIB



PNEUMO



ROTAVIRUS



TYPHOID



YELLOW  
FEVER



HEXAVALENT



DTP  
BOOSTERS



RABIES



Health System  
Support



Equity Accelerator  
Funding



Cold Chain Equipment  
Optimisation Platform

Partner's Engagement Framework –  
Targeted Country Assistance



## Vaccine Support

Gavi provides support in the form of vaccines and associated supplies (e.g., injection safety devices: auto-disable syringes, reconstitution syringes, and safety boxes) for:

- the introduction of vaccines into national immunisation schedules;
- specific and targeted campaigns; and
- subsequent support for these vaccines as part of a country's routine vaccination schedule.

Gavi also funds emergency vaccine stockpiles for countries to use in the event of disease outbreaks.

Gavi requires that the decision to introduce a vaccine into the national immunisation schedule (or via campaigns) should be discussed and supported by a national technical advisory group such as the **National Immunisation Technical Advisory Group (NITAG)**.<sup>1</sup>

Additionally, all countries are required to pay a share of the cost of their Gavi-supported vaccines (i.e. co-financing). As a country's income grows, its co-financing payments gradually increase to cover the full cost of vaccines.

Please refer to the [chapter on co-financing requirements](#) later in these guidelines for additional information.

### Vaccine Introduction Grants (VIGs) and Campaign Operational Support (Ops)

Gavi provides financial support to facilitate the introduction of a new vaccine and/or the effective implementation of a Gavi-supported campaign. This support, referred to as **Vaccine Introduction Grants (VIGs)** and **Campaign Operational Support (Ops)** respectively, provide an opportunity to strengthen routine immunisation services and to facilitate integrated delivery of immunisation with other health interventions. Countries are encouraged to use VIGs and Ops to cover a share of the pre-introduction activities or campaign-related activities, as well as leveraging this opportunity to strengthen vaccine delivery platforms and identify and reach zero-dose children.

Further information on Vaccine Introduction Grants (VIGs) and Campaign Operational support (Ops), including how they are calculated, is provided in the [Gavi Vaccine Funding Guidelines](#).

## Health System Strengthening (HSS) Support

Gavi's HSS grants are intended to help countries make sustainable improvements in immunisation outcomes by strengthening critical elements of their health systems. The primary purpose of these grants is to help countries improve the equity of immunisation and ensure that every child is fully immunised, with a particular focus on reaching zero-dose and under-immunised children. HSS grants can also be used to help countries protect vaccines by strengthening supply chains, building the capacities required for future vaccine introductions, and improving the quality, efficiency, and sustainability of immunisation programmes.

HSS grants are intended to supplement domestic health systems investments and should not typically be used to support routine or recurrent costs. These can be exceptionally considered only where such investments are required to

expand services to reach missed communities and zero-dose children – in which case they should be highly targeted and time-limited with a clear plan for the government to integrate these into the domestic budget over time.

As part of the Gavi Theory of Change in their application for Gavi support, countries should ensure that the design of their HSS grants is aligned with other forms of requested Gavi support – including Cold Chain Equipment (CCEOP), Targeted Country Assistance (TCA), vaccine introduction (VIGs), and operational cost (Ops) grants – to improve immunisation outcomes. Gavi also encourages countries to align Gavi HSS funding with support from other multilateral and bilateral donors to help strengthen immunisation programmes and support integrated delivery of essential primary healthcare (PHC) services.

<sup>1</sup> For more information on NITAGs visit: [https://www.who.int/immunization/sage/national\\_advisory\\_committees/en/](https://www.who.int/immunization/sage/national_advisory_committees/en/)

## Priority areas for Gavi HSS support



Gavi encourages countries to prioritise five primary areas to strengthen their health systems and sustainably reach zero-dose and under-immunised children with quality immunisation services:

- **Leadership, management & coordination:** Ensuring immunisation programmes are well-planned and managed at every level of the health system.
- **Data systems & use:** Ensuring data is fit for purpose and used to manage immunisation services including identifying missed populations, tracking performance, and monitoring vaccine safety.
- **Supply chains:** Ensuring safe and effective vaccines are available wherever and whenever they are needed, with minimal waste or wastage throughout the supply chain.
- **Service delivery:** Ensuring that immunisation services, delivered by high-performing health workers, are routinely available to every community and tailored to the needs of their target populations (ideally as part of an integrated package of essential primary healthcare services).
- **Demand and community engagement:** Building strong demand for and trust in immunisation services through strong communication, civil society, and community engagement.

Gavi strongly encourages countries to ensure that all programming identifies gender-related barriers to immunisation and is gender transformative<sup>2</sup>. Gavi also encourages countries to consider which partners, including civil society organisations, have a comparative advantage in helping to plan and implement HSS grants in each priority area. More information on recommended investments in each of these areas can be found in [Gavi's Programme Funding Guidelines](#).

## Targeting and tailoring Gavi support by context



Interventions supported by Gavi's HSS grants should be targeted and tailored based on context. Countries in earlier development stages with weaker systems and lower immunisation coverage are encouraged to prioritise interventions that build essential programmatic capacities (e.g., cold chain, basic data systems, microplanning) with a focus on areas with disproportionately high numbers of zero-dose and under-immunised children. Countries with stronger health systems and high coverage, and especially those approaching transition, are encouraged to invest in strengthening the quality, efficiency, and sustainability of immunisation services (e.g., redesigning and integrating supply chains, introducing digital data systems, establishing behaviourally informed demand generation interventions<sup>3</sup>) alongside targeted efforts to reach remaining pockets of zero-dose and under-immunised children. Similarly, countries are encouraged to tailor the design of Gavi support by sub-national context. This includes developing tailored strategies for the key settings which have been identified as being home to the majority of zero-dose children: urban areas, conflict settings, and remote rural contexts.

## Health System Strengthening Support Allocation



The Gavi Board has made available US\$1.2 billion in HSS for eligible countries in Gavi 5.0. This funding has been allocated to countries across the Gavi portfolio based on four criteria:

- Number of zero-dose children
- Number of under-immunised children
- Gross national income per capita
- Size of birth cohort

All countries eligible for HSS support from Gavi will be informed how much funding is available for their country by their Senior Country Managers. Country communications will include the [country's HSS "ceiling"](#) (maximum total amount the country can apply for).

<sup>2</sup> Such gender-transformative approaches are those that attempt to redefine and change existing gender roles, norms, attitudes, and practices. These interventions tackle the root causes of gender inequity and inequality and reshape unequal power relations. For caregivers, this can entail creating a more balanced distribution of childcare between both parents, encouraging and celebrating fathers who seek health care for their children, or ensuring women caregivers have the financial means and time available to have their children vaccinated. For health care workers, transformative approaches address pay gaps, unsafe working conditions, sexual violence and exploitation, and poor representation of women in decision-making positions.

<sup>3</sup> I.e., Demand generation interventions that are based on understanding the attitudes and behaviors of care givers.



---

## Equity Accelerator Funding

In December 2020, the Gavi Board approved an additional US\$500 million for the strategic period 2021-2025 as dedicated funding to help countries accelerate efforts to reach zero-dose children and missed communities. The Gavi Board has since extended this funding window until 2027. This funding will be available to countries who identify and develop tailored strategies to reach additional zero-dose children and missed communities that they could not reach using other available resources (including core HSS).

### EAF pre-requisites

All countries eligible for Gavi support can apply to receive EAF, except those with Special Gavi Board approved strategies as of 2021. Countries can access their EAF ceilings for the period 2021-2025 [online](#). **To access EAF, countries will need to establish a baseline on how many, who, and where zero-dose children and missed communities are, as well as the barriers to reach them.** Existing HSS or TCA support can be reprogrammed to develop this baseline. EAF will cover the implementation of robust and ambitious plans to reach zero-dose children and missed communities with tailored strategies. Where resources within HSS/TCA for 'identifying zero dose populations and missed communities' are inadequate, a country may receive exceptional access to some EAF for meeting this pre-requisite step.

### Difference between EAF and HSS

HSS supports countries to build stronger, more equitable, sustainable, and high-quality immunisation programmes. Reaching zero-dose children and missed communities remains a priority for HSS, building on the coverage and equity progress in Gavi 4.0. EAF complements HSS support to further accelerate existing equity programming. There are two major differences between EAF and HSS:

- HSS can be programmed for broader systems strengthening activities. For example, HSS can be used for improving vaccine management, strengthening programme management, or upgrading vaccine-preventable disease surveillance. These activities might indirectly contribute to reaching zero dose children and missed communities but might not specifically target their reach. **The EAF can only be used for activities that are identified as critical to reaching zero-dose children and missed communities in a specific context.**
- **EAF funding is currently only available through 2027.**

---

## Cold Chain Equipment Optimisation Platform (CCEOP)

Within Gavi's Health System Strengthening support is the **Cold Chain Equipment Optimisation Platform (CCEOP)**. Through this platform Gavi jointly invests with countries in the purchase, deployment, and installation of modern, high-performing, cold chain equipment (CCE) as well as in the training of healthcare workers and technicians by suppliers or the suppliers' in-country service providers. CCE serves as a critical component of immunisation programmes and is essential to ensuring that life-saving vaccines reach every child. CCEOP investments should be prioritised to strengthen immunisation services in communities with the largest numbers of zero-dose children.

Similar to the co-financing model for vaccine support, countries are required to jointly invest in CCE procurement with the level of joint investment varying based on a country's transition phase at the time of application. This ranges from Gavi funding 80% of CCE cost for countries in the initial self-financing phase, to 50% for countries in the preparatory and accelerated transition phases. Countries are strongly encouraged to utilise domestic resources or other donor financing for their joint investment. Detailed information on this and additional details of how to plan and apply for CCEOP support can be found in the [Gavi CCEOP Funding Guidelines](#). Countries can access their CCEOP ceilings for the period 2021-2025 [online](#).

---

## Partners' Engagement Framework (PEF) Targeted Country Assistance (TCA)

Gavi provides technical assistance to support countries in introducing vaccines and strengthening routine immunisation programmes through its core partners [WHO, UNICEF, Centers for Disease Control and Prevention (CDC), and the World Bank] and expanded partners (including local institutions) via Targeted Country Assistance (TCA). Gavi supports these partners through the Partners' Engagement Framework (PEF). Technical assistance is expected to:

- be targeted and tailored to countries' needs;
- ensure country focus, transparency, accountability, and differentiation;
- support vaccine and HSS investments;
- help integrate immunisation services into the wider primary healthcare context; and
- increase sustainability of national immunisation services.

When countries undergo their full portfolio planning process during the 5.0 strategic period, TCA support will be planned for and incorporated into a country's Theory of Change and Gavi Support Detail as part of an integrated planning process and request for Gavi support. Details on the first two years of TCA support should be provided in the workplan and should clearly show how they are supportive of the main objectives and activities set out in the application.

TCA is expected to align with [Gavi's programme funding guidelines](#). Gavi strongly promotes consideration of local institutions as TCA providers. Countries can access their TCA ceilings for the period 2021-2025 [online](#).





## Other Support

### Diagnostic Support



Gavi provides support for yellow fever and cholera diagnostic capacity-strengthening through provision of rapid diagnostic tests (cholera only), laboratory supplies, equipment, and capacity-building to countries. The aim of this support is to facilitate more reliable laboratory testing, which in turn should allow for early detection and more effective and efficient vaccine usage, particularly in response to outbreaks and in addressing gaps in routine immunisation coverage identified through detection of yellow fever and cholera cases.

Support for Cholera rapid diagnostics is available to all Gavi-eligible countries, while support for yellow-fever diagnostic support is available to Gavi-eligible African countries classified as “high-risk” for yellow fever by WHO as part of the EYE strategy.<sup>4</sup>

### Global Vaccine Stockpiles



Gavi provides support for global vaccine stockpiles for cholera, meningococcal meningitis, yellow fever, and Ebola vaccines. These stockpiles are managed by the International Coordinating Group (ICG) Secretariat within the World Health Organisation (WHO). Countries experiencing an epidemic may apply for emergency supplies directly through the [ICG Secretariat](#) or through its member agencies. Countries should share their applications with their Senior Country Managers for additional follow-up.

### Support to Middle Income Countries (MICs)



In December 2020, the Gavi Board approved a new approach to engaging with middle-income countries in the Gavi 5.0 strategic period (the “MICs Approach”). Serving as a key tool for addressing threats to the equity and sustainability of routine immunisation programmes, the MICs Approach contributes to Gavi’s overall vision of leaving no one behind with immunisation and has two overarching objectives:

- To prevent backsliding in vaccine coverage in former-Gavi eligible countries; and
- To drive the sustainable introduction of key missing vaccines in both former- and select never-Gavi eligible countries.

Countries eligible under the MICs Approach include all former-Gavi eligible countries, never-Gavi eligible lower middle-income countries (LMICs) and additional IDA-eligible economies. Through the MICs Approach Gavi provides both support at a regional and global level to address the systemic issues that

stand in the way of sustainable and equitable new vaccine introductions, alongside tailored support in response to country-specific needs in line with the MICs Approach objectives. This includes support to mitigate backsliding in a select group of former-Gavi eligible countries that have seen significant and sustained reductions in vaccine coverage as well as country-specific support to drive the sustainable and equitable introduction of PCV, rotavirus, and HPV vaccines.

### The COVAX Facility



COVAX is the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, which is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines.

[COVAX](#) is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI), and WHO. Its aim is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world. Gavi is coordinating the development and implementation of the COVAX Facility, the global procurement mechanism of COVAX.

### COVID-19 vaccine Delivery Support (CDS)



COVAX seeks to support countries to rapidly and equitably scale-up COVID-19 vaccines. To this end, Gavi provides a funding opportunity to all AMC-eligible COVAX participants to support vaccine delivery, with a particular focus on accelerating vaccinations of high and high-risk populations (as defined by SAGE), supporting scale-up to reach country targets for adult vaccinations, and integrating COVID-19 and routine immunisations to achieve sustainable benefits. This COVID-19 vaccine Delivery Support (CDS) is intended to be closely aligned with, and complementary to, domestic funding support from other donors, multilateral development banks, and agencies. Countries can program CDS funding to end of 2023.

### Innovation Top-up



Innovation in Gavi 5.0 is defined as the use of new products, practices, and services that unlock more efficient and effective ways to accelerate countries’ immunisation objectives in line with Gavi’s mission. If a country has needs in their immunisation programme that could be addressed by innovative interventions and has already explored funding from all support available, the country can request Innovation Top-up funding. The top-up funding aims to support scaling up of proven innovations as per the [Programme Funding Guidelines](#).

# 3 The Application Process



There are two paths to requesting new Gavi support in 2022, as further described below, depending on the status of your current portfolio with Gavi.

## Pathway 1

Countries who are preparing a new Health System Strengthening (HSS) request will undertake a full portfolio planning (FPP) process to comprehensively plan for a multi-year period for all Gavi support, including HSS funds, CCE support, Technical Assistance, Equity Accelerator Funding, and any vaccine introductions or campaigns during the same period.

When to use	What support type	How	Key elements
Countries whose current HSS grant is coming to an end	HSS, CCEOP, TCA, EAF, new vaccine support	Full Portfolio Planning (FPP), using 5.0 application materials	One Gavi Application for all types of Gavi support for a multi-year period

## Pathway 2

Countries who will not undergo a full portfolio planning in the foreseeable future (e.g. as they are in the middle of an ongoing HSS grant cycle) can still apply for additional individual support on an as-needed basis.

When to use	What support type	How	Key elements
Countries mid-way in ongoing HSS grant cycle	New vaccine support, EAF, CCEOP, TCA	New vaccine support: via Country Portal Other support: via dedicated channel provided by SCM	Stand-alone requests are expected to complement existing support and to contribute to the goals and expected outcomes for the strategic period



## New Approaches under Gavi 5.0 for Applying for Gavi Support

Along with the updates to Gavi's strategic approach, the Secretariat has made efforts to re-design the application process in an effort to simplify the process in the long-term, create efficiencies, and enable further flexibilities for countries.

**Please note that the application changes outlined in this section are principally applicable for countries as they enter their full portfolio planning (FPP) process (Pathway 1).**

### Theory of change grounded in reaching zero-dose children



Countries will be required to develop a Theory of Change (ToC) as part of the full portfolio planning process.<sup>4</sup> The Theory of Change component convenes immunisation stakeholders to develop a long-term vision spanning several years for how Gavi support will contribute to their national immunisation system and how they will reach zero-dose children and missed communities. Collectively, stakeholders will develop goals and objectives and determine what activities and Gavi support will be needed to achieve them. This ToC process and thinking provides the foundation for the Gavi application and request for support and is a necessary mapping to be included with the country's application.

### Integrated portfolio of support



In the past, countries submitted separate applications for different types of Gavi support on an as needed basis. In the revised approach for Gavi 5.0, countries will develop their Theory of Change, map out support they will need, and submit one integrated request for all types of Gavi support – HSS grants, CCEOP, TCA funding, EAF, and vaccine support. Integrating the country's request into a single application and portfolio approach will help to create synergies across support types and enable a single review and approval process for multiple types of Gavi support. Although encouraged, countries do not have to apply for all support types desired across their grant period at the same time but can build their portfolio via standalone applications.

### Multi-Year Approvals



During the Theory of Change process, the country and stakeholders will develop a vision spanning multiple years for what support they would like to request from Gavi and how this support will be translated into results via activities and objectives. This portfolio and multi-year planning approach will enable a comprehensive review by the Independent Review Committee (IRC) and approval for a package of Gavi support across several years.

### Differentiated approach



Gavi recognises that country needs, capacities, and contexts vary. Gavi has created differentiated application and portfolio management processes to better suit countries across these contexts.

The integration of these changes into country applications is a key shift in processes in Gavi 5.0. This integration and how countries will undergo their FPP process is outlined below by 'Pathway 1'. However, countries that are not yet due to undergo their FPP process can continue to apply for vaccine support (see below: 'Pathway 2') via the [Country Portal](#) and posted [IRC dates](#).

<sup>4</sup>Fragile & Conflict countries are encouraged but are not required to do a Theory of Change mapping for their support request.

## Pathway 1 – Countries Conducting their FPP Process

As a first step in the FPP, countries are expected to compile and review existing country data and reflect their insights in the [Situational Analysis Checklist](#). The purpose of this step is to inform the programming of Gavi funds by identifying critical programmatic barriers and evidence gaps to guide which should be prioritised. It is a pre-requisite to continuing on to the next step of the application process: the Gavi Theory of Change.

The **Theory of Change** (ToC) is a collaborative process designed to map out national immunisation goals and objectives and how Gavi support will help achieve them.<sup>5</sup>

After developing a ToC, countries will build a portfolio view for the upcoming three to five years **across all types of existing and new support provided by Gavi** (i.e. HSS and CCEOP support, vaccine support, EAF, and PEF-TCA). Through this portfolio planning approach, countries will match Gavi support to country-driven strategies and interventions for achieving national goals and objectives for reaching immunisation targets.

Countries will be expected to include any anticipated new vaccine introductions and campaigns supported by a required detailed request for any new vaccine support scheduled within the first 24 months. Throughout the portfolio planning exercise, countries should ensure coordination and integration of the different types of Gavi support, including the appropriate sequencing, and

timing of future vaccine introductions and/or planned campaigns. This integration is documented through the **Gavi Support Detail**.

Taking a portfolio perspective on Gavi support will ensure that all investment streams work toward achieving shared and complementary goals outlined in the Theory of Change.




Technical Country Assistance (TCA) needs should be considered and planned for during the FPP.

For further information, [Gavi Programme Funding Guidelines](#) can be used to inform dialogue processes and decisions when planning for support and can also provide ideas for innovative approaches and support informed decision-making around evidence-based examples.



The coordination of stakeholders, data gathering and analyses, and ToC process can take several months. Developing your three to five-year request for support with accompanying budget and mandatory attachments can also be an extensive process. Therefore, you should plan to begin your application process approximately 6 months prior to when you would like to submit your application.



<sup>5</sup>While all countries are encouraged to develop a Theory of Change, it is not mandatory for Fragile & Conflict countries as an accompaniment to their submission.



## Step 1: Situational Analysis

- First, **connect with your Senior Country Manager** to learn about what the application process will entail. You should discuss intentions for what type of Gavi support you'd like to request for over the course of a five-year period and when you would like to submit a Gavi application. The timing of the request period can, for example, be aligned with national planning cycles.
- Your Senior Country Manager will share with you a **Gavi application package** that is tailored to your country's context.
- Included in your application kit will be the **Situational Analysis Checklist**. You should review the required analyses and corresponding analytical questions and start compiling existing country and immunisation data to inform your responses.
- These **required analyses** will inform which interventions to prioritise for Gavi support in your next step: the Theory of Change.

### Outputs

- [Situational Analysis Checklist](#)

## Step 2: The Theory of Change (ToC)

- For detailed guidance on how to conduct a ToC, please refer to the [ToC Instructions](#).
- First, **map out then convene all relevant stakeholders and partners** in a participatory and transparent manner. Stakeholders should play a key role in the development of the country's ToC.
- Develop your ToC. This should be a collaborative undertaking between the Ministry of Health, Alliance partners, Expanded Partners, Civil Society Organisations (CSOs), other relevant stakeholders, and the Gavi Secretariat. The ToC should serve as a tool for planning, managing, and evaluating Gavi support towards your immunisation programme.
- Prepare your [Strategic Narrative](#). The narrative will provide you with an opportunity to describe how Gavi support will help you realise your ToC.
- By the end of the ToC process, you will have completed a **ToC mapping** (using either your own or a Gavi-provided template) and a **Strategic Narrative**.



All types of support being requested by the country, such as CCEOP, new vaccine introductions or campaigns, and TCA support, must be included within the Theory of Change template, costed workplan, and Strategic Narrative. Required attachments will need to be submitted alongside their mention in these integrated plans.

### Theory of Change




### Outputs

- [Theory of Change mapping](#)
- [Strategic Narrative](#)

### Step 3: Gavi Support Detail & Budget

- After you have completed your ToC process, you will map out a comprehensive plan of requested Gavi support and the activities that you will undertake to achieve the stated outcomes and objectives. This plan is your **Gavi Support Detail**. The [Gavi Support Detail Instructions](#) within your application kit includes comprehensive directions for how to complete the following tabs of the Gavi Support Detail:



#### Costed workplan

Vaccine Portfolio

Grant-linked Key Performance Indicators & Learning

Targeted Areas

The workplan will provide an overview of the Gavi support requested, including activities across different support types, such as HSS, TCA, and vaccine support. It should include any new vaccine introductions or campaigns anticipated for the planning period.

Costed workplan

#### Vaccine Portfolio

Grant-linked Key Performance Indicators & Learning

Targeted Areas

For any **new vaccines** that you would like to incorporate into your portfolio within **24 months of the submission date of your application**, you should complete this tab.

Prior to your official submission, Gavi will review and provide you with calculated allocations and co-financing projections for the new vaccines that you plan to introduce, and flag these updates for you to review prior to your final submission.

Costed workplan

Vaccine Portfolio

#### Grant-linked Key Performance Indicators & Learning

Targeted Areas

Detailed instructions for completing your Grant-linked Key Performance Indicators & Learning tab can be found in the [Gavi Support Detail Instructions](#).

Costed workplan

Vaccine Portfolio

Grant-linked Key Performance Indicators & Learning

#### Targeted Areas

Gavi will provide a pre-populated list of geographic areas (at the second administrative, or district, level) for you to indicate where Gavi HSS, EAF, and other support is targeted.



In addition to the Gavi Support Detail which will help map out all your requests, targets, goals, and activities, you will need to complete a detailed **budget**<sup>6</sup>. Instructions for completing the budget are included in your application kit.

### Outputs

- Gavi Support Detail:
  - Costed Workplan
  - New Vaccine Support Details (first 24 months)
  - Key Performance Indicators & Learning
  - Targeted Areas mapping
- Budget

<sup>6</sup>Depending on a segmentation approach done by Gavi, some countries are only required to provide a costed workplan without the requirement for a detailed budget. This will be discussed with the Senior Country Manager.

## Step 4: Completion Checklist & finalising your application

Depending on the type of support for which you are applying, there may be **additional requirements for your application**. For example, if you are applying for new measles or measles-rubella support, you will also need to include a five-year measles strategic plan. For any additional materials, please refer to the **mandatory attachments list** that is included in your application kit.

Once you have reviewed your application for completeness and accuracy and have had an exchange with Gavi regarding your vaccine allocations, the final

step before submission is to ensure that your application receives the relevant signatures from both the Minister of Health and the Minister of Finance (and if applying for HPV, the Minister of Education) and endorsements from the national Coordination Forum.

### Outputs

- Quality and completion review
- Upload all required attachments and needed endorsements



### Submitting your application

Your Senior Country Manager will provide you with a link to your customised application kit – a set of folders where you will find instructions, templates, forms, and locations for mandatory uploads. Once your application package is complete and the required endorsements have been uploaded, you should notify your Senior Country Manager that you are ready to submit. Submission times and modalities should be planned for and discussed early in the process with your Senior Country Manager as they will differ based on country context. After your submission, the Secretariat will screen your application for validity and consistency and to ensure that mandatory requirements have been met. If there are any concerns, the Secretariat will be in touch to resolve any outstanding issues.



**Note:** When conducting the FPP process countries will include detailed requests for vaccine introductions for the first 24 months of their grant cycle and reflect any new vaccine support beyond the initial 24 months in their ToC, Workplan, and narrative. For vaccine introductions planned to occur later than 24 months from the FPP submission date, countries will need to submit a request for the new vaccine support closer to that time, including information on targets, vaccine requirements, vaccine introduction plans etc. Such later vaccine requests will be subject to an independent review. Please refer to Pathway 2.







## Pathway 2 – Countries Mid-Grant Cycle

Gavi countries who are mid-grant cycle can continue to apply for new support on an as-needed basis. Countries submitting a stand-alone application should factor into their planning opportunities for integration and complementarity with existing Gavi support. Submission deadlines are published on the Gavi [website](#) (deadlines are usually early Q1, Q2, and end of Q3).

### Application materials and submission

When **requesting new vaccine and /or campaign support outside of an FPP process**, countries will fill in the vaccine application online on the [Country Portal](#). Requirements pertaining to each specific type of vaccine support are available in the [Gavi Vaccine Funding Guidelines](#). The Country Portal opens approximately two months prior to the submission deadline. The online vaccine application form can be downloaded once a minimum set of information has been entered into the system. E-learning modules are available to support applicants; additional information can be found [here](#).

Countries wanting to **request EAF or CCEOP support before the start of their FPP process**, should contact their respective Senior Country Manager to obtain a tailored set of application materials.



The coordination of stakeholders and national coordination forum to plan for new support, such as an introduction or campaign can take several months. You should begin your planning and application process 4-6 months prior to when you would like to submit your application.

Also, ensure that the target vaccine introduction (or campaign) date and plans for preparatory activities are compatible with the timelines for the likely receipt of Gavi funds and vaccines. It will usually not be feasible for a country to introduce a vaccine less than 15-18 months after the Gavi application submission deadline.

After your submission, the Secretariat will screen your application for validity and consistency and to ensure that mandatory requirements have been met. If there are any concerns, the Secretariat will be in touch to resolve any outstanding issues.



## Review by the Independent Review Committee

A country's request for new support is reviewed by Gavi's Independent Review Committee (IRC). The IRC is comprised of experts in public health, epidemiology, supply chain, development finance, economics, and other relevant fields. The IRC will review countries' request for support in accordance with policies adopted by the Gavi Board and advise on whether to fund country plans and programmes. The aim of the IRC review is to make a recommendation as to whether a country's plan will likely achieve (i.e., on a balance of probabilities) the proposed results and contribute to Gavi achieving its mission and strategy, taking into account the country's justification, soundness of approach, country readiness, feasibility of plans, system strengthening and sustainability, economic and financial considerations, and public health benefit of the investment in line with Gavi's mission. The IRC will consider country support requests holistically, especially assessing linkages

and continuity between programmes. They also take into consideration reports on country performance and country-specific reviews, in making its recommendations.

The IRC normally meets three times a year, typically end of Q1, end of Q2/early Q3, and in Q4 to review stand-alone vaccine requests (as described in Pathway 2). However, countries developing their full portfolio planning should consult with their SCM to determine the timeline for their submission.

When planning your application process, you should anticipate when you might like to have your application reviewed by the IRC and plan enough time to ensure that the development process, application preparation, final checks, and pre-screening by the Secretariat can all occur before your targeted IRC date.

### A successful request will:

- ✓ Clearly articulate how countries will identify and reach zero-dose children and missed communities;
- ✓ Show how countries will programme and differentiate the use of all streams of requested support (e.g., vaccine introduction grants, HSS, TCA, etc.), to target zero-dose children and missed communities;
- ✓ Show integration of services and strategies, including across antigens, to not only strengthen routine immunisation within the country but enable delivery of other primary healthcare services as well;
- ✓ Ensure integration of Gavi support with existing national or subnational health sector and/or immunisation plans.
- ✓ Demonstrate broad participation in planning, design, and implementation across diverse country partners and stakeholders, including local partners and civil society.  
**At least 10% of combined HSS, EAF, and TCA ceilings should be used for CSO implementation.**
- ✓ Strategically invest in the strengthening and improvement of vaccine programmes, including in areas such as supply chain; data systems and use; leadership, management, and coordination; and demand and community engagement. Attention should be given to investments in innovations in these areas with potential to dramatically improve zero-dose coverage and overall equity of vaccine programme reach.

## Potential Review Outcomes

The reviewers will make one of the following recommendations to Gavi (to be captured in the independent review report):

### For all Gavi support applied



#### Recommend Gavi approval:

for a situation where there are no issues that require a re-review by the IRC. Reviewers may however identify issues to be addressed before the final approval of the support.



#### Recommend the re-review of outstanding issues:

for a situation where there are issues that require a re-review by the IRC. This implies that there are material issues that need to be met and/or that there are major gaps to be addressed by the country before approval by Gavi.

- The independent reviewers may identify outstanding issues to be addressed and complementary strengthening actions. These outstanding issues need to be clarified (i.e., either resolved or an action plan for their resolution should be developed) by the country within a specific time period (typically within 30 working days). The Gavi Secretariat will review the country's responses and determine whether the issues have been satisfactorily cleared or not.
- During this period, the Gavi Secretariat will also work with the country to finalise details that form part of the approval, documented in the Decision Letter, and the disbursement decision. This may include the finalisation and agreement on key documents, such as the detailed budget, the finalisation of grant management arrangements, and TCA-related resourcing.
- The independent reviewers have identified material issues with the request, and subsequently, need to review the country's response to the identified issues and revised application materials. The country should respond to each issue by providing a detailed summary of the changes made in response to the issues raised. Depending on the nature of the issues identified by the reviewers, it may require a substantial revision of the request and submission of updated and/or additional information. The resubmitted application and information/ documents require updated signatures and endorsement by the Ministers of Health and Finance (and if applicable Education for HPV) and the National Coordination Forum.
- The recommendation from the IRC will be shared with the country and partners via an Information Letter within 2-3 weeks following the independent review.<sup>7</sup> Your Gavi Senior Country Manager will provide more information as you move through the review process.

<sup>7</sup>For FPP reviews, a debrief presentation from the reviewers may be scheduled with key country stakeholders.





## Application Approval

Gavi's Chief Executive Officer (CEO) will consider and decide on the final grant documents, based on recommendations from the independent review. Countries and partners are notified of the final outcome through a Decision Letter.

The following are some key steps to be carried out post-Gavi approval.<sup>8</sup> Your Gavi Senior Country Manager will advise you on the steps relevant to your country status.

Prior to grant implementation, a Programme Capacity Assessment (PCA<sup>9</sup>) is conducted by an external contractor appointed by Gavi, if not already completed prior to the independent review. Additional reviews relating to checks on unused funds in a country (if the country has previously received financial support) will also be carried out by the Gavi Secretariat. Key terms are included in a Grant Management Requirement (GMRs) document,

which forms an annex to the Partnership Framework Agreement (PFA) between Gavi and the country.<sup>10</sup>

Gavi will also initiate internal processes for the transfer of funds to countries and/ or vaccine purchase (with UNICEF SD)<sup>11</sup>. The country should begin to plan activities to prepare for the vaccine introduction, for example discussing with the UNICEF country office regarding shipment plans, ensuring country product licensing requirements are met, etc.<sup>12</sup>

Countries with cold chain equipment should work with UNICEF SD to agree on final pricing, model section by year, and delivery timelines. If financing the joint investment share through national resources or partner resources<sup>13</sup>, such countries should also agree on the appropriate US\$ amount and transfer the joint investment to UNICEF SD.<sup>14</sup>



**If you have any questions regarding Gavi support or how to complete your application, please reach out to your Senior Country Manager.**

<sup>8</sup> In the exceptional case that there is a significant delay (two years or longer) following the submission and subsequent approval of a country's vaccine application and the actual introduction of the vaccine (or campaign), updated information on the planned introduction (such as an updated introduction plan, targets, and cold chain capacity) will need to be submitted.

<sup>9</sup> The Programme Capacity Assessment (PCA) ensures that a country's programme, financial, and vaccine and cold chain management are robust and transparent in line with Gavi's Transparency and Accountability Policy (TAP).

<sup>10</sup> The PFA sets out the terms and conditions by which Gavi provides support and the country undertakes to implement Gavi-supported programmes.

<sup>11</sup> Details on procurement of vaccines, including requirements for self-procuring countries and cold chain equipment can be found here: [Guidance on procurement](#).

<sup>12</sup> Each country may have its own vaccine licensing requirement. The Ministry of Health is responsible for facilitating this process with National Regulatory Authority and the manufacturer of the chosen product. UNICEF SD may provide support.

<sup>13</sup> Gavi will transfer the country's joint investment share directly to UNICEF SD on behalf of countries using an existing HSS grant.

<sup>14</sup> Disbursement of Gavi's joint investment is contingent on UNICEF SD confirming receipt of the country's joint investment share.

# Key strategic considerations for 'Gavi 5.0'

## Gavi 5.0 Strategic Goals

“Leaving no one behind with immunisation” by 2030 is the vision for Gavi’s strategic period 2021-25. This vision is driven by the following four strategic goals:

- |       |  |   |  |   |
|-------|--|---|--|---|
| Goals | <b>1</b> INTRODUCE AND SCALE UP VACCINES | <b>2</b> STRENGTHEN HEALTH SYSTEMS TO INCREASE EQUITY IN IMMUNISATION | <b>3</b> IMPROVE SUSTAINABILITY OF IMMUNISATION PROGRAMMES | <b>4</b> ENSURE HEALTHY MARKETS FOR VACCINES AND RELATED PRODUCTS |
|-------|--|---|--|---|

- |            |  |  |   |   |
|------------|--|--|---|---|
| Objectives | <p><b>A</b> Strengthen countries’ <b>prioritisation of vaccines</b> appropriate to their context</p> <p><b>B</b> Support countries to <b>introduce</b> and <b>scale up coverage of vaccines</b> for prevention of endemic and epidemic diseases</p> <p><b>C</b> Enhance <b>outbreak response</b> through availability and strategic allocation of vaccine stockpiles</p> | <p><b>A</b> Help countries extend immunisation services to regularly <b>reach under-immunised and zero-dose children</b> to build a stronger primary health care platform</p> <p><b>B</b> Support countries to ensure <b>immunisation services</b> are <b>well-managed, sustainable, harness innovation</b>, and meet the needs of all caregivers</p> <p><b>C</b> Work with countries and communities to build resilient <b>demand</b>, and to identify and address <b>gender-related barriers</b> to immunisation</p> | <p><b>A</b> Strengthen national and subnational <b>political and social commitment</b> to immunisation</p> <p><b>B</b> Promote <b>domestic public resources for immunisation and primary health care</b> to improve allocative efficiency</p> <p><b>C</b> Prepare and engage <b>self-financing countries</b> to maintain or <b>increase performance</b></p> | <p><b>A</b> Ensure sustainable, <b>healthy market dynamics</b> for vaccines and immunisation-related products at affordable prices</p> <p><b>B</b> Incentivise <b>innovation</b> for the development of <b>suitable vaccines</b></p> <p><b>C</b> Scale up <b>innovative immunisation-related products</b></p> |
|------------|--|--|---|---|

## Gavi 5.0 Operating Principles

### Missed communities are the first priority

**Equity** remains a key organising principle of Gavi's support. This will entail ensuring that priority is put on extending services to communities that are currently missed including refugees, displaced, and other vulnerable populations.

### Gender focused

Recognising the strong connection between gender-related barriers and immunisation inequities, a **gender lens** should be applied to all requests for support.

### Country-led, sustainable

A more deliberate approach to balance short-term health systems support and long-term **health systems strengthening** and to bolster **country leadership** to sustainably deliver and finance immunisation.

### Community-owned

**Community ownership** and **trust** should be at the center of interventions designed to create **demand for immunisation services** and to improve service delivery for under-served populations.

### Differentiated

Interventions should be targeted and tailored to their **specific national and sub-national context**.

### Integrated

Systematic coordination with other donors and financing institutions and exploration of new partnerships to promote integration and multisectoral approaches to **disease control and prevention**.

### Adaptive

Countries and communities can leverage immunisation to address **major global developments** including climate change, Global Health Security, antimicrobial resistance (AMR), and urbanisation.

### Innovative

Accelerating innovation across the portfolio will include a **broader strategy for vaccine-related products** and a path to **scale up innovative practices and services** that can unlock equity bottlenecks at the local level.

### Collaborative, accountable

Gavi has collaboration as a core principle for all of its work. Continuing to **expand collaboration** beyond the core partnerships, with new expanded partners, civil society organisations (CSOs), other donors and financing institutions, and exploring **new partnerships** to promote integration and multisectoral approaches to disease control and prevention.



## Equity & Reaching Zero-Dose Children

**Requests for Gavi support under the 5.0 strategy should be grounded in sustainably reaching zero-dose children and missed communities with a drive to achieve equity in immunisation.**

The Alliance has made equity the organising principle of Gavi 5.0, with an acute focus on reaching zero-dose and under-immunised children with immunisation. This is also a key priority for the global community's Immunization Agenda 2030, which was endorsed by the World Health Assembly in May 2020.

Even before the COVID pandemic, one in five children were not receiving a full course of basic vaccines in Gavi-supported countries, while more than one in ten were not even receiving a first dose of routine vaccines.<sup>15</sup> With the impact of COVID-19, it is likely that many more children are under-immunised or considered zero-dose today.

Zero-dose children often live in missed communities that face multiple deprivations, including socio-economic inequities and lack of access to health services, which can be further exacerbated by gender-related barriers. Two-thirds of zero-dose children live in households which are below the poverty line. Many live in urban slums, remote rural areas, fragile and conflict settings, or in households facing acute social, political, cultural, and gender-related barriers to accessing immunisation. Communities with large numbers of zero-dose and under-immunised children are more vulnerable to outbreaks of vaccine-preventable diseases and are often ill-equipped to respond to an outbreak.

Reaching zero-dose and under-immunised children with a full schedule of vaccines is the primary objective of Gavi 5.0. Countries are encouraged to use the zero-dose lens when considering programming the full range of Gavi support available to them. Extending immunisation services to these children and their communities can be the first step towards comprehensive primary healthcare.

**Identifying who these children are, why they are missed, and how they can be reached sustainably should be the starting point for countries in planning their Gavi support.** This diagnosis and the subsequent development of a Theory of Change to address zero-dose children and missed communities can provide opportunities for multi-sector, multi-agency / coalitions to drive broader social change.

As described further in [Gavi's Programme Funding Guidelines](#), and illustrated below, the Alliance is proposing a common framework for countries to design tailored programmes to reach zero-dose children and missed communities, against which Gavi support can be programmed. Sometimes referred to as the "IRMMA Framework," it reflects the following components:



**Identify** where zero-dose children and missed communities are and why they are missed



**Reach** these communities sustainably with differentiated context-dependent programmatic approaches



**Monitor** the implementation of programmes that aim to reach zero-dose children




**Measure** the effectiveness and efficiency of programmes



**Advocate** for zero-dose children and missed communities with one voice as an Alliance

<sup>15</sup> These figures refer to DTP3 and DTP1, as defined above for under-immunised versus zero-dose children.

## Using Zero-Dose Strategy to Strengthen Primary Health Care across the Life Course



As countries think how to utilise Gavi support, they are encouraged to use this framework to guide their thinking on zero-dose children and under-immunised communities.

# Eligibility and Co-Financing



## Gavi Eligibility Requirements

Gavi aims to focus its support on the world's poorest countries and therefore bases eligibility for support on national income. Countries become eligible for Gavi support if their Gross National Income (GNI) per capita has been less than or equal to US\$ 1,730 in the latest available World Bank data.<sup>16</sup>

Based on a country's GNI per capita, Gavi classifies all eligible countries into "transition" phases, for which specific eligibility rules and co-financing requirements apply. These phases are:

- **Initial self-financing phase:** countries with GNI per capita equal to or below US\$1,085
- **Preparatory transition phase:** countries with GNI per capita between US\$1,085 and US\$1,730
- **Accelerated transition phase:** countries with GNI per capita above the US\$1,730 threshold<sup>17</sup> when its three-year average GNI p.c. as well as its most recent GNI p.c. are above the eligibility threshold, and the country is co-financing at least 35% of vaccine costs.

- **Fully self-financing countries:** countries that have completed the accelerated transition phase and are paying 100% of the cost of vaccines.

If a country surpasses the threshold for its current phase following the release of World Bank GNI per capita data in July of that year, the country will be informed by Gavi in September of the same year. During the first year in a new phase the eligibility rules and co-financing requirements from the previous phase still apply.

Once a country crosses the eligibility threshold, it enters the accelerated transition phase and starts to phase out of Gavi's financial support.

In line with the December 2022 Gavi Board decision<sup>18</sup> a country in accelerated transition can apply for new vaccine support during the full eight years of their accelerated transition, while continuing to co-finance the vaccine in line with Gavi policy.<sup>19</sup>

Additional conditions apply to specific vaccine support, which are detailed in the [Gavi Vaccine Funding Guidelines](#) (e.g. financing of first dose of measles).


<sup>16</sup> Gavi uses World Bank GNI data (based on the Atlas method) released in July of each year. This data is for the annual GNI of a country in the previous year (i.e. in July 2022, the World Bank releases GNI data for 2021). Thus, for eligibility to apply in 2023, Gavi will consider the GNI data for 2021. Due to the exceptional Gavi Board decision to freeze eligibility in 2021, the same threshold was used in 2021 as for 2020, as well as the same average GNI of years 2016, 2017, and 2018. The eligibility threshold is revised annually to adjust for inflation.

<sup>17</sup> That is: When a country's reported three-year average GNI p.c. as well as its most recent GNI p.c. is above this threshold, Gavi will inform the country that it will enter the accelerated transition phase effective January 1st of the coming year.

<sup>18</sup> Refer to: Decision 12b, part a.

<sup>19</sup> See the following section for more details on applying for new vaccines during accelerated transition.





Low-income countries (GNI per capita below US\$ 1,085 in 2021) are classified as "initial self-financing"

As their income per capita increases, they enter a "preparatory transition" phase.

Countries then enter eight year of "accelerated transition" once they cross the Gavi eligibility threshold (US\$ 1,730 per capita in 2022).

At the end of eight years, they become fully self-financing.




# Available Gavi vaccine support and eligibility by country

The chart below provides an overview of a country's Gavi-supported vaccine portfolio (as of 2023) and transition phase for purposes of better understanding which vaccines a country is eligible for but has not yet introduced and country obligations for vaccine co-financing.

## COUNTRY VACCINE INTRODUCTIONS, ELIGIBILITY, AND TRANSITION STATUS AS OF 2023

### AFRICAN REGION



### TRANSITION STATUS AS OF 2024

Benin	R	R	R	D	E	E	R	E		E	E	A	R		RC	RC	E		E	E	E	E	E	RC			E	E		
Burkina Faso	R	R	R	DR	R	A	RC	R		E	E	A	R		RC	RC	RC		E	E	E	E		A	RC			E	E	
Burundi	R	R	R	D	A	A	RC	E		E	E	A	R		RC	RC	C	E			E	E	E				E	E		
Cameroon	R	R	R	DR	R	A	R	A		E	A	A	R			RC	C	E				E	E	E	E	RC			E	E
Central African Republic	R	A	R	E	E	E	R	E		E	E	A		E			RC		E	E	E	E	E	E	RC			E	E	
Chad	R	E	E	E	E	E	R	R		E	E	A		RC	E	E	RC		E	E	E	E		E	R	A		E	E	
Comoros	R	E	E	E	E	E	RC	A		E	E				RC	RC					E	E		E				E	E	
Congo	R	R	R	E	E	E	R	A		E	E				RC						E	E	E		RC	E		E	E	
Côte d'Ivoire	R	R	R	DR		A	RC	E		E	E	A		RC	RC	RC	RC		E	E	E	E	E	E	RC			E	E	
DR Congo	R	R	R	E	E	E	R	A		E	A	A		A	E	E	C	E			E	E	E	E	RC			E	E	
Eritrea	R	R	R	RC	R	C	RC	R		E	E	E	R		RC	RC	RC		E	E	E	E		E				E	E	
Ethiopia	R	R	R	DR	R	A	R	A		E	E	E	R	R			C	E			E	E		E	E	E		E	E	
Gambia	R	R	R	DRC			R	R		E	A	A	R	R	RC	RC	RC		E	E		E		E			E	E	E	
Ghana	R	R	R	D	E	E	RC	A		E	E	A	R	R	RC	RC	RC		E	E	E	E		E	RC			E	E	
Guinea	R	E	E	E	E	E	R	R		E	E	A	A	R	E	E	R	R	E	E	E	E	E	E	RC			E	E	
Guinea-Bissau	R	R	R	E	E	E	R	E		E	E	E		R	A	A		R	E	E	E	E	E	E	R	E	E	E	E	
Kenya	R	R	R	DR		A	R	E		E	E	A			RC	RC	C	E			E	E		E	R	E		E	E	

Initial self-financing

Preparatory transition

Accelerated transition

Fully self-financing

## COUNTRY VACCINE INTRODUCTION, ELIGIBILITY, AND TRANSITION STATUS AS OF 2023

COUNTRY VACCINE INTRODUCTIONS, ELIGIBILITY, AND TRANSITION STATUS AS OF 2023

Pentavalent

Rotavirus

Pneumococcal

Human papillomavirus

Routine

Multi-age cohort vaccination

Inactivated polio1,2

Inactivated polio1,2 – 1st Dose Routine

Japanese encephalitis

Cholera (preventive)

Cholera diagnostic support

Malaria

Measles<sup>3</sup> – 1st Dose Routine

Measles<sup>3</sup> – 2nd Dose Routine

Measles-rubella<sup>4</sup> – 1st Dose Routine with catch up campaign

Measles-rubella<sup>4</sup> – 2nd Dose Routine with catch up campaign

Meningitis A<sup>6</sup> Routine, with catch up campaign

Preventative mass vaccination campaign

MMCV

Routine and/or preventive mass vaccination campaign

HepB birth dose

Rabies

Ebola preventive

Typhoid

Yellow fever Routine and/or preventive mass vaccination campaign

Yellow fever and/or preventive mass vaccination campaign

COVID-19

Hexavalent

DTPcv Boosters<sup>5</sup>

Initial self-financing

Preparatory transition

Accelerated transition

Fully self-financing

AFRICAN REGION	Pentavalent	Rotavirus	Pneumococcal	Human papillomavirus	Routine	Multi-age cohort vaccination	Inactivated polio1,2	Inactivated polio1,2 – 1st Dose Routine	Japanese encephalitis	Cholera (preventive)	Cholera diagnostic support	Malaria	Measles <sup>3</sup> – 1st Dose Routine	Measles <sup>3</sup> – 2nd Dose Routine	Measles-rubella <sup>4</sup> – 1st Dose Routine with catch up campaign	Measles-rubella <sup>4</sup> – 2nd Dose Routine with catch up campaign	Meningitis A <sup>6</sup> Routine, with catch up campaign	Preventative mass vaccination campaign	MMCV	Routine and/or preventive mass vaccination campaign	HepB birth dose	Rabies	Ebola preventive	Typhoid	Yellow fever Routine and/or preventive mass vaccination campaign	Yellow fever and/or preventive mass vaccination campaign	COVID-19	Hexavalent	DTPcv Boosters <sup>5</sup>	Initial self-financing	Preparatory transition	Accelerated transition	Fully self-financing
Lesotho	R	R	R	RC	R	C	R	E					R	RC	RC					E	E					E	E						
Liberia	R	R	R	DR		A	RC	E				A	R	R						E	E	E	RC	RC			E	E					
Madagascar	R	R	R	D	E	E	R	R					R	R						E	E					E	E						
Malawi	R	R	R	DR		A	RC	E				A	R		RC	RC				E	E		RC				E	E					
Mali	R	R	R	D	A	E	R	R					R		E	E	RC		E	E	E	E	E	E	RC			E	E				
Mauritania	R	R	R	RC	R	C	R	E					R	RC	R	C	E					E					E	E					
Mozambique	R	R	R	D	R	A	R	A				A	R		RC	RC					E	E					E	E					
Niger	R	R	R	D	E	E	R	R				A			E	E	RC		E	E	E	E			E	R	E			E	E		
Nigeria	R	A	R	A	A	A	R	R					RC	R			RC		E	E					E	RC			E	E			
Rwanda	R	R	R	R	R		R	R					R		RC	RC	E	E			E	E	E	E				E	E				
Sao Tome and Principe	R	R	R	D	R	C	RC	E					R		RC	RC					E				E	R			E	E			
Senegal	R	R	R	DR	R	A	RC	A					R		RC	RC	C	E					E	E	E	RC			E	E			
Sierra Leone	R	R	R	DR	R	A	RC	R					R		RC	RC					E	E	E	E	RC			E	E	E			
South Sudan	R	E	E	E	E	E	R	R				A					C	E							E	E	E	E	E			E	E
Togo	R	R	R	D	A	A	R	R					R		RC	RC	RC		E	E	E	E			E	RC			E	E			
Uganda	R	R	R	R	R		R	R				A			RC	A	C	E					E	E	E	E	RC			E	E		
UR Tanzania	R	R	R	DR	R	A	RC	E					R		RC	RC	E	E					E	E	E	E			E	E			
Zambia	R	R	R	DR	R	A	RC	E					R		RC	RC					E	E	E	E				E	E				
Zimbabwe	R	R	R	DRC	R	C	RC	R					R		RC	RC					E	E		RC				E	E				



## COUNTRY VACCINE INTRODUCTION, ELIGIBILITY, AND TRANSITION STATUS AS OF 2023



## REGION OF THE AMERICAS

Haiti


## EASTERN MEDITERRANEAN REGION

Afghanistan	R	R	R	E	E	E	R	R		E	E		C		E	E						E		E				E	E																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																				
-------------	---	---	---	---	---	---	---	---	--	---	---	--	---	--	---	---	--	--	--	--	--	---	--	---	--	--	--	---	---	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

## EUROPEAN REGION

Kyrgyzstan	R	R	R	RC	R	C	R	R		E	E											E		E				E	E			
Tajikistan	R	R	R	E	E	E	RC	R		E	E											E		E				E	E			

# COUNTRY VACCINE INTRODUCTIONS, ELIGIBILITY, AND TRANSITION STATUS AS OF 2023



## SOUTH-EAST ASIAN REGION

	Pentavalent	Rotavirus	Pneumococcal	Human papillomavirus	Routine	Multi-age cohort vaccination	Inactivated polio 1,2 - 1st Dose Routine	Inactivated polio 1,2 - 2nd Dose Routine	Japanese encephalitis	Cholera (preventive)	Cholera diagnostic support	Measles 3 - 1st Dose Routine	Measles 3 - 2nd Dose Routine	Measles-rubella 4 - 1st Dose Routine with catch up campaign	Measles-rubella 4 - 2nd Dose Routine with catch up campaign	Meningitis A6 Routine, with catch up campaign	MMRV Routine, with catch up campaign	HepB birth dose	Rabies	Ebola preventive	Typhoid	Yellow fever	Routine and/or preventive mass vaccination campaign	Yellow Fever diagnostic support	COVID-19	Hexavalent	DTPcv Boosters 5	Initial self-financing	Preparatory transition	Accelerated transition	Fully self-financing
Bangladesh	R	A	R	D	A	A	RC	E	A	E	E	R	RC	RC				E	E					E	E						
DPR Korea	R	E	E	E	E	E	R	E	E	E	E	R	RC					E		E				E	E						
India	R	R	R		E	E	R	E	RC				C																		
Myanmar	R	R	R	R	R	A	R	A	RC	E		R	RC	RC				E		E											
Nepal	R	R	R	D	E	E	RC	E	RC	E		R	RC	RC				E	E		A										

## WESTERN PACIFIC REGION

	Pentavalent	Rotavirus	Pneumococcal	Human papillomavirus	Routine	Multi-age cohort vaccination	Inactivated polio 1,2 - 1st Dose Routine	Inactivated polio 1,2 - 2nd Dose Routine	Japanese encephalitis	Cholera (preventive)	Cholera diagnostic support	Measles 3 - 1st Dose Routine	Measles 3 - 2nd Dose Routine	Measles-rubella 4 - 1st Dose Routine with catch up campaign	Measles-rubella 4 - 2nd Dose Routine with catch up campaign	Meningitis A6 Routine, with catch up campaign	MMRV Routine, with catch up campaign	HepB birth dose	Rabies	Ebola preventive	Typhoid	Yellow fever	Routine and/or preventive mass vaccination campaign	Yellow Fever diagnostic support	COVID-19	Hexavalent	DTPcv Boosters 5	Initial self-financing	Preparatory transition	Accelerated transition	Fully self-financing
Cambodia	R	E	R	D	A	A	R	E	RC	E		R	RC	RC				E		E											
Lao PDR	R	A	R	DRC	R	C	R	E	C	E		R	C	RC				E		E											
Papua New Guinea	R		R	SE	SE	SE	R	R		E		R	C					E		E											
Solomon Islands	R	R	R	DRC	R	C	R	E				R	C					E		E											

### Introduction type

**R** - Introduction of a routine programme   **C** - Campaign   **D** - Demonstration   **A** - Approved, awaiting introduction

### Eligibility type

☐ Not yet introduced a routine or campaign   **E** - Eligible   **SE** - Requiring special board decision   ☒ Not eligible

<sup>1</sup> Approval for IPV catch-up campaign: Côte D'Ivoire, Eritrea, Kyrgyzstan, Malawi, Mongolia, Rwanda, Senegal, Sierra Leone, Togo, Uzbekistan, Zimbabwe

<sup>2</sup> Eligibility for IPV catch-up campaign: DPR Korea, Djibouti, Gambia, Guinea-Bissau, Lesotho, Nepal

<sup>3</sup> Second dose of M or MR vaccine as second dose of measles containing vaccine. The list excludes measles follow-up campaigns as they are not directly associated with routine introductions. They are supplementary immunisation activities to fill measles immunity gaps.

<sup>4</sup> MR vaccine as rubella containing vaccine. Eligibility in this list is based on WUENIC 2019 data and survey coverage of the last M/MR

campaigns and may change based on latest available data. Please refer to the MR programme guidance for details of the eligibility criteria. The list excludes measles-rubella follow-up campaigns as they are not directly associated with routine introductions. They are supplementary immunisation activities to fill measles immunity gaps.

<sup>5</sup> Support to introduce any of the three recommended DTP-containing vaccine boosters into the routine immunisation schedule. Countries that have a booster programme are not eligible for support for that existing touchpoint, except for those deciding to switch from DTP to pentavalent or hexavalent in the 2YL

<sup>6</sup> Countries that may have conducted MenA preventive mass vaccination campaign are still eligible for routine immunisation or routine immunisation with catch up campaigns.

---

## Co-Financing Requirements

Co-financing of vaccines and injection devices is one of the ways in which Gavi-supported countries contribute to their immunisation costs. Countries are required to co-finance all Gavi-supported vaccines in the routine immunisation schedule – except IPV – and additionally for measles or measles rubella follow-up campaigns.

Co-financing is expected to increase country ownership of vaccine financing, build capacity relating to procurement processes, and ensure that countries are on a trajectory towards financial sustainability and the eventual phasing out of Gavi support.

### 1 What is co-financing?

- Governments co-finance the cost of Gavi-supported vaccines by procuring a share of the vaccine doses and injection safety devices directly from a procurement agent, with Gavi covering the rest. Co-financing is not a payment made to Gavi.
- Co-financing obligations include the cost of vaccines, related injection safety devices (not required for countries in initial self-financing phase), and freight charges. Costs and fees of procurement agencies are not included.
- The co-financed share per year gradually increases as the country moves through the various transition phases.

### 2 What Gavi vaccine support does co-financing requirement apply to?

- All Gavi-supported vaccines in the routine immunisation schedule. This includes the routine cohort immunisation for HPV (there is no co-financing requirement for the multi-age cohort) and excludes IPV standalone vaccine; and
- Measles or Measles Rubella follow-up campaigns.

### 3 Are there other conditions or requirements for co-financing?

- Countries must not use Gavi resources (including HSS support) to pay for co-financing obligations.
- Country co-financing commitments must be fulfilled by 31 December of each year except for countries with whom it is agreed to have co-financing aligned with a non-calendar fiscal year.<sup>20</sup>
- If a country does not meet its co-financing commitments, Gavi will consider halting its support in such circumstances pursuant to the default mechanism in [Gavi's co-financing policy](#).
- Countries should clearly indicate in their request for new vaccine support how co-financing commitments will be funded including the sources of funds (governments and/or donor) and discuss how predictable and reliable these resources are. If the country has recently defaulted on its co-financing obligations, countries should clearly indicate the steps taken to mitigate the likelihood of further defaults.

---

<sup>20</sup> In these cases, the obligations are due by 30 June of each year.



## 4 How are co-financing amounts communicated?

- Estimates of co-financing commitments are provided directly in the Gavi Support Detail (Tab 3) based on country inputs. However, official co-financing commitments are ultimately communicated through the Decision Letter following Gavi approval of vaccine support.

## 5 How is co-financing applied?

Country co-financing obligations are determined based on the country's transition phase as set out below:

### Initial self-financing:

- Countries are required to co-finance a small proportion of doses every year, equivalent to US\$0.20 per dose of all co-financed vaccines.<sup>21</sup>

US \$0.20



### Preparatory transition:

- Countries are required to co-finance an increasing share of the weighted average price (WAP) of the vaccine presentation.
- In the first year, the country still pays the US\$0.20 as per the initial self-financing phase. The total fraction paid in the first year determines the share to be paid in subsequent years for all co-financed vaccines. This fraction increases of 15% per year.<sup>22,23</sup>
- New vaccines introduced during this phase are co-financed at the same fraction of the vaccine price (based on weighted average price) as other vaccines.

Y1



+15% every year



**Example:** A country enters the preparatory transition phase in 2020 and has pentavalent and PCV in its portfolio. In 2020, the country applies to introduce the rotavirus vaccine in 2021. The amounts and share that it pays for its current portfolio in 2020 are:

$$(\$400,000 + \$700,000) / [(\$400,000 + \$700,000) + (\$3,000,000 + \$8,000,000)] = \$1.1\text{m} / \$12.1\text{m} = 9.1\%$$

Vaccine	Co-financing amount in 2020	Gavi support in 2020	Total	Price fraction in 2020
Pentavalent	\$400,000	\$3,000,000	\$3,400,000	—
PCV	\$700,000	\$8,000,000	\$8,700,000	—
<b>Total</b>	<b>\$1,100,000</b>	<b>\$11,000,000</b>	<b>\$12,100,000</b>	<b>9.1%</b>

The country's price fraction increases by 15% per year and is applied to all vaccines including Rota. In 2021 this would lead to:  $9.1\% \times 1.15 = 10.5\%$ .

This fraction is then multiplied by the unloaded<sup>24</sup> price of each vaccine, as well as the total volume of doses, to reach the co-financing amount in USD.

<sup>21</sup> There is an exception for MR for which the co-financing per dose is US\$ 0.30 and for the 3-dose schedule Rota presentation for which it is US\$ 0.13.


<sup>22</sup> The 15% increase is calculated on the price fraction. For example, if a price fraction is 10%, the price fraction will increase by 15% to 11.5%.

<sup>23</sup> There is an exception for Measles and MR for which it is the co-financing per dose of respectively US\$ 0.20 and US\$ 0.30 that increases by 15% per year.

<sup>24</sup> Gavi defines a "price per dose" or the "unloaded price" in US\$ for the vaccines it supports. This unit price - for a single dose of a specified vaccine and refers to the cost of the vaccine dose alone; it does not include associated expenditures such as freight, cold-chain costs, administrative costs, and wastage.

### Accelerated transition

- For countries in the first year of this phase, the price fraction increases by 15% (the same as it did in the preparatory transition phase).
- The amount per dose then increases linearly over the subsequent years to ensure that countries are paying the full projected Gavi price of the vaccine in their first year following the end of Gavi support.



### New vaccine support requested during the accelerated transition phase

Countries can apply for new vaccine support in any of the eight years of the accelerated transition phase.<sup>25</sup>

The number of years of support for which the country is eligible is based on the year in which the country introduces the vaccine.

The introductory fractions for new vaccine applications in the accelerated transition phase are determined by the year of application.<sup>26</sup>

- For countries applying in the first year of the accelerated transition phase, the introductory co-financing per dose will be based on the price fraction and vaccine price of the first year of accelerated transition phase. For the remaining years after the introduction, the co-financing amount per dose will increase linearly towards the full projected Gavi price for the first year without Gavi support.
- For countries applying in one of the subsequent years in the accelerated transition phase, the co-financing fraction used to determine the co-financing per dose is shown in the table below.

This applies for all vaccines other than measles and measles-rubella routine, for which the co-financing per dose in the introduction year will be \$0.20 per dose and \$0.30 per dose respectively.

Application Year	Introductory price fraction
1	As applied to other vaccines
2	40%
3	50%
4	60%
5	70%
6	80%
7 and 8	90%
Fully self-financing	100%



You should contact your Senior Country Manager if you plan to request new vaccine support during the accelerated transition phase to discuss the co-financing implications in more detail.

<sup>25</sup> Note that both the application submission and the recommendation for approval from the IRC must occur during the accelerated transition phase.

<sup>26</sup> The application year is determined by the year in which the New Vaccine Support application window closes (often referred to as "Rounds").